DOCS vs. ESPR
DOCS (Doximity, Inc.) and ESPR (Esperion Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — DOCS in Health Information Services, ESPR in Biotechnology. Over the past 3 years, DOCS returned -14.86%/yr vs 35.36%/yr for ESPR. At a 0.23 correlation, their price movements are largely independent.
Performance
DOCS vs. ESPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DOCS achieves a -54.74% return, which is significantly lower than ESPR's -14.86% return.
DOCS
- 1D
- 0.10%
- 1M
- -14.32%
- YTD
- -54.74%
- 6M
- -54.30%
- 1Y
- -64.81%
- 3Y*
- -14.86%
- 5Y*
- —
- 10Y*
- —
ESPR
- 1D
- 0.00%
- 1M
- 0.96%
- YTD
- -14.86%
- 6M
- -18.18%
- 1Y
- 162.50%
- 3Y*
- 35.36%
- 5Y*
- -34.62%
- 10Y*
- -14.95%
DOCS vs. ESPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
DOCS Doximity, Inc. | -54.74% | -17.06% | 90.41% | -16.45% | -33.05% | 21.76% |
ESPR Esperion Therapeutics, Inc. | -14.86% | 68.18% | -26.42% | -52.01% | 24.60% | -77.52% |
Correlation
The correlation between DOCS and ESPR is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Jun 24, 2021 | 0.23 |
Fundamentals
DOCS:
$3.91B
ESPR:
$791.76M
DOCS:
$0.98
ESPR:
-$0.03
DOCS:
6.19
ESPR:
1.75
DOCS:
$644.86M
ESPR:
$418.24M
DOCS:
$574.54M
ESPR:
$226.32M
DOCS:
$245.76M
ESPR:
$77.18M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DOCS vs. ESPR — Risk / Return Rank
DOCS
ESPR
DOCS vs. ESPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Doximity, Inc. (DOCS) and Esperion Therapeutics, Inc. (ESPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DOCS | ESPR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.96 | ||
| Sortino ratioReturn per unit of downside risk | -4.82 | ||
| Omega ratioGain probability vs. loss probability | 0.72 | 1.36 | -0.64 |
| Calmar ratioReturn relative to maximum drawdown | -0.85 | 3.07 | -3.93 |
| Martin ratioReturn relative to average drawdown | -1.43 | 7.68 | -9.11 |
Loading charts...
Drawdowns
DOCS vs. ESPR - Drawdown Comparison
The maximum DOCS drawdown since its inception was -82.35%, smaller than the maximum ESPR drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for DOCS and ESPR.
Loading charts...
Drawdown Indicators
| DOCS | ESPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.35% | -99.37% | +17.02% |
Max Drawdown (1Y)Largest decline over 1 year | -76.03% | -53.19% | -22.84% |
Max Drawdown (3Y)Largest decline over 3 years | -78.34% | -80.94% | +2.60% |
Max Drawdown (5Y)Largest decline over 5 years | — | -97.16% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.10% | — |
Current DrawdownCurrent decline from peak | -80.36% | -97.27% | +16.91% |
Average DrawdownAverage peak-to-trough decline | -57.18% | -69.99% | +12.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 45.49% | 21.30% | +24.19% |
Volatility
DOCS vs. ESPR - Volatility Comparison
Doximity, Inc. (DOCS) has a higher volatility of 29.57% compared to Esperion Therapeutics, Inc. (ESPR) at 1.06%. This indicates that DOCS's price experiences larger fluctuations and is considered to be riskier than ESPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DOCS | ESPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.57% | 1.06% | +28.51% |
Volatility (6M)Calculated over the trailing 6-month period | 44.93% | 61.44% | -16.51% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.14% | 92.66% | -38.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.07% | 91.79% | -21.72% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.07% | 84.61% | -14.54% |
Dividends
DOCS vs. ESPR - Dividend Comparison
Neither DOCS nor ESPR has paid dividends to shareholders.
Financials
DOCS vs. ESPR - Financials Comparison
This section allows you to compare key financial metrics between Doximity, Inc. and Esperion Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DOCS vs. ESPR - Profitability Comparison
DOCS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Doximity, Inc. reported a gross profit of 125.97M and revenue of 145.37M. Therefore, the gross margin over that period was 86.7%.
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
DOCS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Doximity, Inc. reported an operating income of 24.83M and revenue of 145.37M, resulting in an operating margin of 17.1%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
DOCS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Doximity, Inc. reported a net income of 19.11M and revenue of 145.37M, resulting in a net margin of 13.2%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
Frequently Asked Questions
DOCS and ESPR have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DOCS has higher volatility (29.57%) compared to ESPR (1.06%). In terms of maximum drawdown, DOCS dropped -82.35% vs ESPR's -99.37%.
ESPR currently has the higher Sharpe Ratio (1.76 vs -1.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DOCS and ESPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer